2023, www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
Post-protocol maintenance After resolving primary injury concerns, some users transition to long-term maintenance protocols
First, there is supporting evidence for the safety of GLP-1RAs across the board of cognitive and mental disorders, as we retrieved very few studies 44,159,181,182,193,205 suggesting worse neuropsychiatric outcomes associated with these medications (Tables 16, Fig
A few, including Wegovy, Zepbound, and Saxenda (liraglutide), are FDA-approved for weight loss
However, a 24 week washout period is recommended to allow IGF-1 receptor density and insulin sensitivity to normalize after prolonged ligand exposure, as continuous receptor activation downregulates receptor transcription and can blunt responsiveness to subsequent cycles
Are GLP 1 & GIP Based Therapies for everyone who wants to lose weight